VanEck Pharmaceutical ETF
PPH
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 666 Third Avenue, 9th Floor New York NY United States of America 10017
- IPO Date
- Feb 1, 2000
- CIK
- 0001137360
- Website
- vaneck.com
- Similar Companies
- Business
- VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that seeks to replicate, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. The fund tracks the overall performance of the 25 largest and most liquid U.S.-exchange-listed companies involved in pharmaceuticals, including research and development; production; and marketing and sales of pharmaceutical products and services. Top holdings as of late 2025 include Eli Lilly & Co (LLY, 24.41%), Novartis AG (NVS, 9.09%), Merck & Co Inc (MRK, 7.72%), Novo Nordisk A/S (NVO, 6.05%), and GSK Plc (GSK, 4.73%), with additional significant positions in Johnson & Johnson (JNJ), Pfizer Inc (PFE), Bristol-Myers Squibb Co (BMY), McKesson Corp (MCK), AstraZeneca Plc (AZN), AbbVie Inc (ABBV), Sanofi SA (SNY), and Cencora Inc (COR); the portfolio is concentrated in healthcare (99.84% weighting), with geographic exposure spanning the United States (64.82%), United Kingdom (11.85%), Switzerland (8.69%), Denmark (6.04%), France (4.12%), Japan (2.25%), and Israel (2.07%). PPH, with total net assets of approximately $1.14 billion and an expense ratio of 0.36%, trades on the Nasdaq and targets investors seeking concentrated exposure to established global pharmaceutical leaders based on market capitalization and trading volume. Launched on December 20, 2011 and issued by VanEck, a New York City-headquartered investment manager founded in 1955, the ETF is part of VanEck's broad lineup of over 100 ETFs focused on sectors, asset classes, and smart beta strategies. In recent years, VanEck has pursued strategic expansions including the August 2025 launch of TruSector ETFs for uncapped sector exposure using hybrid equity-ETF structures; the October 2025 debut of the EMBX active emerging markets bond ETF; and the December 2025 rebranding of its gaming ETF to the VanEck Degen Economy ETF to capitalize on digital economy trends, alongside ongoing portfolio monitoring evidenced by the 2024 liquidation of underperforming products like the Dynamic High Income ETF (INC).